Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.78−0.70 (-4.83%)
Close on Nov 18, 2026Market cap $1.22BP/E –Yield –
Mineralys Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Mineralys Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$138.79M. For fiscal 2025 it was -$142.42M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$142.42M | – |
| FY2024 | Dec 31, 2024 | -$166.31M | – |
| FY2023 | Dec 31, 2023 | -$81.17M | – |
| FY2022 | Dec 31, 2022 | -$29.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$45.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$66.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.58M | – |
See a number that looks wrong?